India's Shaily Engineering rises after UBS notes likely gain from Zydus diabetes drug row
BUZZ-India's Shaily Engineering rises after UBS notes likely gain from Zydus diabetes drug row ** Shaily Engineering SEPL.NS rises as much as 3.69% to 3,184 rupees
** UBS notes plastics and pharma packaging maker as potential beneficiary after Delhi High Court on Wednesday directed drug regulator CDSCO to review Zydus Lifesciences' ZYDU.NS semaglutide injection approval
** "Potential change in vendor could open opportunity for SEPL after a diabetes patient alleged that ZYDU departed from the global practice of pre-filled, pre-calibrated pen devices," says UBS
** UBS retains "buy", PT 4,000 rupees, implying 30.3% upside from last close
** Average rating of six analysts on SEPL is "strong buy" with median PT at 3,477 rupees - LSEG-compiled data
** SEPL up about 36% in 2026 so far
(Reporting by Bharath Rajeswaran in Bengaluru)
((bharath.rajeswaran@thomsonreuters.com; +91 9769003463;))
Recent news on Zydus Lifesciences
See all newsIndia's Zydus Lifesciences posts lower profit as expenses outpace revenue growth
Brief: Zydus Lifesciences Q2 Consol Net Profit 9.26 Billion Rupees
Brief: Zydus Lifesciences Says Zylidac Bio And Prolific Machines Partner
Brief: Zydus Lifesciences Receives U.S. FDA Approval For Estradiol And Levonorgestrel Transdermal System
Brief: Zydus Lifesciences Says Zydus Sunshine Lifesciences Signs Agreement To Establish A Pharmaceutical Manufacturing Facility In Sri Lanka